The need for performance-based payment models is likely to increase in the future, not least due to stepwise introduction of new therapies and rapid developments within the field of ATMP.
IHE has a long-standing interest in the development of new payment models in order to
- reduce uncertainty around costs and benefits
- optimize and individualize treatments to avoid over- or under treatment
- drive faster uptake of new, effective pharmaceuticals
- stimulate the development of new technologies
Examples of areas where IHE has developed new payment models include haemophilia, multiple sclerosis and psoriasis.